Literature DB >> 22520470

Small molecule bromodomain inhibitors: extending the druggable genome.

Chun-Wa Chung1.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22520470     DOI： 10.1016/B978-0-12-396493-9.00001-7

Source DB:  PubMed          Journal:  Prog Med Chem        ISSN： 0079-6468


× No keyword cloud information.
  18 in total

Review 1.  Epigenetic drug discovery: breaking through the immune barrier.

Authors:  David F Tough; Paul P Tak; Alexander Tarakhovsky; Rab K Prinjha
Journal:  Nat Rev Drug Discov       Date:  2016-10-21       Impact factor: 84.694

Review 2.  Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11.

Authors:  David F Tough; Huw D Lewis; Inmaculada Rioja; Matthew J Lindon; Rab K Prinjha
Journal:  Br J Pharmacol       Date:  2014-11       Impact factor: 8.739

3.  Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.

Authors:  Natalie H Theodoulou; Paul Bamborough; Andrew J Bannister; Isabelle Becher; Rino A Bit; Ka Hing Che; Chun-wa Chung; Antje Dittmann; Gerard Drewes; David H Drewry; Laurie Gordon; Paola Grandi; Melanie Leveridge; Matthew Lindon; Anne-Marie Michon; Judit Molnar; Samuel C Robson; Nicholas C O Tomkinson; Tony Kouzarides; Rab K Prinjha; Philip G Humphreys
Journal:  J Med Chem       Date:  2015-04-30       Impact factor: 7.446

4.  BET Inhibition Attenuates Helicobacter pylori-Induced Inflammatory Response by Suppressing Inflammatory Gene Transcription and Enhancer Activation.

Authors:  Jinjing Chen; Zhen Wang; Xiangming Hu; Ruichuan Chen; Judith Romero-Gallo; Richard M Peek; Lin-Feng Chen
Journal:  J Immunol       Date:  2016-04-15       Impact factor: 5.422

5.  Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.

Authors:  Shuai Liu; Hailemichael O Yosief; Lingling Dai; He Huang; Gagan Dhawan; Xiaofeng Zhang; Alex M Muthengi; Justin Roberts; Dennis L Buckley; Jennifer A Perry; Lei Wu; James E Bradner; Jun Qi; Wei Zhang
Journal:  J Med Chem       Date:  2018-08-30       Impact factor: 7.446

6.  Chromatin effector Pygo2 mediates Wnt-notch crosstalk to suppress luminal/alveolar potential of mammary stem and basal cells.

Authors:  Bingnan Gu; Kazuhide Watanabe; Peng Sun; Magid Fallahi; Xing Dai
Journal:  Cell Stem Cell       Date:  2013-05-16       Impact factor: 24.633

7.  Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA.

Authors:  Z Zou; B Huang; X Wu; H Zhang; J Qi; J Bradner; S Nair; L-F Chen
Journal:  Oncogene       Date:  2013-05-20       Impact factor: 9.867

Review 8.  Privileged diazepine compounds and their emergence as bromodomain inhibitors.

Authors:  Steven G Smith; Roberto Sanchez; Ming-Ming Zhou
Journal:  Chem Biol       Date:  2014-04-17

9.  Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit.

Authors:  Brian S Gerstenberger; John D Trzupek; Cynthia Tallant; Oleg Fedorov; Panagis Filippakopoulos; Paul E Brennan; Vita Fedele; Sarah Martin; Sarah Picaud; Catherine Rogers; Mihir Parikh; Alexandria Taylor; Brian Samas; Alison O'Mahony; Ellen Berg; Gabriel Pallares; Adam D Torrey; Daniel K Treiber; Ivan J Samardjiev; Brian T Nasipak; Teresita Padilla-Benavides; Qiong Wu; Anthony N Imbalzano; Jeffrey A Nickerson; Mark E Bunnage; Susanne Müller; Stefan Knapp; Dafydd R Owen
Journal:  J Med Chem       Date:  2016-05-03       Impact factor: 7.446

10.  Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signaling.

Authors:  Xuewei Wu; Jun Qi; James E Bradner; Gutian Xiao; Lin-Feng Chen
Journal:  J Biol Chem       Date:  2013-11-04       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.